首页> 外文会议>IEEE International Symposium on Biomedical Imaging >A method for quantification of calponin expression in myoepithelial cells in immunohistochemical images of ductal carcinoma in situ
【24h】

A method for quantification of calponin expression in myoepithelial cells in immunohistochemical images of ductal carcinoma in situ

机译:原位免疫组织化学图像中肌上皮细胞中钙酞素表达的量化方法

获取原文

摘要

Ductal carcinoma in situ (DCIS) is breast cancer confined within mammary ducts, surrounded by an intact myoepithelial cell layer that prevents local invasion. A DCIS diagnosis confers increased lifetime risk of developing invasive breast cancer (IBC) and results in surgical excision with radiation, and possibly endocrine- or chemo-therapy. DCIS is known to be over treated, with associated co-morbidities. Biomarkers are needed that delineate patients at low risk of DCIS progression from patients requiring more aggressive treatment. Investigating the role of myoepithelial cell differentiation in barrier function is anticipated to provide insight into DCIS progression and delineate between low and high risk lesions. Here, we develop a high throughput technique to assess loss of myoepithelial differentiation markers. This method facilitates automated analysis of a clinically relevant histopathologic feature, as demonstrated by a high correlation with pathologist annotation (r = 0.959), and further, contributes analytical foundations to a multiplexed immunohistochemistry (IHC) approach.
机译:导管癌原位(DCIS)是乳腺癌局限于乳腺导管内,被完整的肌上皮细胞层包围,可防止局部侵袭。 DCIS诊断促进了患有侵入性乳腺癌(IBC)的寿命风险,并导致手术切除辐射,并且可能是内分泌或化学治疗。已知DCIS过度治疗,具有相关的共同病态。需要生物标志物,以患者在需要更积极的患者的患者处于低风险的患者划分患者。研究了肌上皮细胞分化在屏障功能中的作用,预计会对低风险病变之间的DCIS进展和描绘进行洞察。在这里,我们开发了一种高吞吐量技术,以评估肌上皮微分标记的丧失。该方法有助于对临床相关的组织病理学特征的自动分析,如通过与病理学家注释(R = 0.959)的高相关(R = 0.959),进一步促进分析基础,以多路复用免疫组织化学(IHC)方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号